non-Hodgkin lymphoma (Cancer)
Information
- Disease name
- non-Hodgkin lymphoma
- Disease ID
- DOID:0060060
- Description
- "A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma." [url:http\://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma, url:http\://www.cancer.gov/dictionary?CdrID=45148]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02553447 | Active, not recruiting | N/A | Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency | October 19, 2015 | March 24, 2025 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT04082936 | Active, not recruiting | Phase 1/Phase 2 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | September 30, 2019 | October 2024 |
| NCT04060277 | Active, not recruiting | Phase 2 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | November 27, 2019 | April 7, 2030 |
| NCT05665725 | Active, not recruiting | Phase 1 | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma | January 31, 2023 | December 31, 2025 |
| NCT05688475 | Active, not recruiting | Phase 1 | A Rollover Study of CC-122 | April 11, 2023 | February 25, 2026 |
| NCT01333046 | Active, not recruiting | Phase 1 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | January 2012 | September 27, 2027 |
| NCT03713580 | Active, not recruiting | Phase 1 | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma | March 12, 2019 | June 1, 2024 |
| NCT04035434 | Active, not recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | July 22, 2019 | August 2026 |
| NCT00576654 | Active, not recruiting | Phase 1 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | December 5, 2007 | June 30, 2023 |
| NCT03573310 | Active, not recruiting | Phase 1 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | July 13, 2018 | December 31, 2024 |
| NCT03570892 | Active, not recruiting | Phase 3 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | May 7, 2019 | February 14, 2026 |
| NCT04000880 | Active, not recruiting | N/A | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health | March 4, 2020 | August 31, 2024 |
| NCT05205512 | Active, not recruiting | N/A | Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial | September 14, 2022 | October 29, 2024 |
| NCT03997968 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | October 9, 2019 | December 30, 2024 |
| NCT05320809 | Active, not recruiting | Phase 1 | Study of 3D189 in Patients With Hematologic Malignancies | August 1, 2022 | December 2024 |
| NCT03560752 | Active, not recruiting | Phase 1 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | August 20, 2018 | June 18, 2024 |
| NCT03467373 | Active, not recruiting | Phase 1 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | March 13, 2018 | October 30, 2024 |
| NCT03434769 | Active, not recruiting | Phase 1 | AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | July 9, 2018 | February 2036 |
| NCT04545333 | Active, not recruiting | The clonoSEQ® Watch Registry | October 13, 2020 | December 2024 | |
| NCT03192397 | Active, not recruiting | Phase 1/Phase 2 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | August 9, 2017 | May 21, 2027 |
| NCT02732275 | Active, not recruiting | Phase 1 | DS-3201b in Participants With Lymphomas | March 31, 2016 | December 31, 2024 |
| NCT00709033 | Active, not recruiting | Phase 1 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | July 2009 | April 2027 |
| NCT03904134 | Active, not recruiting | N/A | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) | June 14, 2019 | March 2025 |
| NCT02631044 | Active, not recruiting | Phase 1 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | January 6, 2016 | May 10, 2024 |
| NCT02290951 | Active, not recruiting | Phase 1 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | January 9, 2015 | December 2, 2025 |
| NCT02595866 | Active, not recruiting | Phase 1 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | April 4, 2016 | October 11, 2024 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT03755414 | Active, not recruiting | Phase 1 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | September 4, 2019 | September 5, 2024 |
| NCT04896580 | Active, not recruiting | N/A | IIT2020-20-SHIRAZIP-WALK: Nature Walks | June 21, 2021 | May 2024 |
| NCT04459416 | Active, not recruiting | Phase 3 | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | June 30, 2020 | June 2025 |
| NCT02506933 | Active, not recruiting | Phase 2 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | November 5, 2015 | December 30, 2024 |
| NCT05974410 | Available | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | |||
| NCT01032681 | Completed | Phase 1 | EMD 521873 in Advanced Solid Tumors, MTD Finding | December 2006 | January 2012 |
| NCT01097057 | Completed | Phase 2 | Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells | November 9, 2010 | December 26, 2017 |
| NCT01141959 | Completed | Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients | May 2010 | December 2011 | |
| NCT01164696 | Completed | A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin | August 2007 | May 2009 | |
| NCT01181258 | Completed | Phase 2 | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | August 2010 | July 2016 |
| NCT01328626 | Completed | Phase 1 | A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma | May 23, 2011 | May 8, 2020 |
| NCT01344876 | Completed | Phase 1 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | April 2011 | April 2014 |
| NCT01447056 | Completed | Phase 1 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | February 2012 | January 22, 2020 |
| NCT01487031 | Completed | N/A | Music Therapy on Nausea and Pain for Autologous Stem Cell | November 2011 | April 2013 |
| NCT01516619 | Completed | Phase 2 | Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia | November 2011 | November 2012 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT01593696 | Completed | Phase 1 | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | June 29, 2012 | October 2, 2017 |
| NCT01597778 | Completed | Phase 3 | Double Cord Versus Haploidentical (BMT CTN 1101) | June 2012 | September 11, 2020 |
| NCT01611298 | Completed | N/A | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | March 2008 | July 2013 |
| NCT01634217 | Completed | Phase 1 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | November 8, 2013 | December 1, 2018 |
| NCT01685008 | Completed | Phase 2 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | April 23, 2013 | April 6, 2022 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01768845 | Completed | N/A | Unrelated Umbilical Cord Blood (UBC)Transplantation | February 3, 2009 | April 6, 2021 |
| NCT01777152 | Completed | Phase 3 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | January 31, 2013 | October 2, 2020 |
| NCT01796171 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma | December 2012 | October 27, 2022 |
| NCT01810120 | Completed | Phase 1/Phase 2 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | January 2012 | December 2016 |
| NCT01871675 | Completed | Phase 1 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | May 2013 | June 2016 |
| NCT01900509 | Completed | Phase 1 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | August 2013 | May 2016 |
| NCT01939327 | Completed | Phase 2 | Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma | September 2013 | January 2020 |
| NCT01947140 | Completed | Phase 1/Phase 2 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | September 9, 2013 | September 1, 2022 |
| NCT01951885 | Completed | Phase 3 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | July 7, 2014 | August 11, 2021 |
| NCT01953692 | Completed | Phase 1 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | November 22, 2013 | June 26, 2020 |
| NCT02104427 | Completed | Phase 2 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | February 2015 | November 2015 |
| NCT02142530 | Completed | Phase 1 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | October 2014 | January 2018 |
| NCT02280785 | Completed | Phase 2 | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | November 2014 | September 2018 |
| NCT02406092 | Completed | Phase 3 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | October 13, 2015 | June 30, 2021 |
| NCT02410252 | Completed | N/A | Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies | May 2015 | August 2017 |
| NCT02432235 | Completed | Phase 1 | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | October 5, 2015 | October 24, 2019 |
| NCT02488369 | Completed | N/A | Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents | March 31, 2011 | January 25, 2018 |
| NCT01596621 | Completed | Phase 3 | A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment | August 6, 2012 | April 24, 2017 |
| NCT00026910 | Completed | Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma | July 1998 | May 2002 | |
| NCT00039910 | Completed | Phase 3 | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | July 2000 | March 2003 |
| NCT00089596 | Completed | Phase 1/Phase 2 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | March 2004 | October 2006 |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT00103779 | Completed | Phase 1 | A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma | December 2004 | March 2007 |
| NCT00113724 | Completed | Phase 1 | Study of TPI 287 in Patients With Advanced Malignancies | May 2005 | January 2008 |
| NCT00143559 | Completed | Phase 2 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | August 2005 | January 2009 |
| NCT00152139 | Completed | Phase 3 | Stem Cell Transplantation for Patients With Hematologic Malignancies | May 2002 | January 2009 |
| NCT00177554 | Completed | Phase 2 | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | November 2003 | May 2007 |
| NCT00185965 | Completed | Phase 1/Phase 2 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | July 2004 | March 2010 |
| NCT00187161 | Completed | Phase 2 | Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL | November 1994 | January 2007 |
| NCT00196885 | Completed | Phase 2 | Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training | December 2003 | December 2006 |
| NCT00302757 | Completed | Phase 1/Phase 2 | Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | March 2006 | July 2011 |
| NCT00306111 | Completed | Phase 2 | Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma | January 2006 | December 2011 |
| NCT00341705 | Completed | The Second Multicenter Hemophilia Cohort Study | April 27, 2001 | April 2, 2013 | |
| NCT00342004 | Completed | A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women | May 1, 1997 | July 28, 2020 | |
| NCT00374699 | Completed | Phase 1/Phase 2 | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | April 2006 | October 2009 |
| NCT00398411 | Completed | Phase 3 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | October 2006 | December 2008 |
| NCT00444912 | Completed | Phase 2 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | February 2006 | June 2009 |
| NCT00503451 | Completed | Phase 1 | A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors | September 2007 | |
| NCT00509379 | Completed | Phase 2 | Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma | September 2006 | January 2011 |
| NCT00539695 | Completed | Phase 2 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | June 2007 | March 2014 |
| NCT00556452 | Completed | Phase 1/Phase 2 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | October 2007 | September 2012 |
| NCT00644371 | Completed | Phase 2 | Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) | November 2007 | February 4, 2013 |
| NCT00859768 | Completed | N/A | The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients | April 2008 | October 2010 |
| NCT00923520 | Completed | Phase 1 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | March 25, 2009 | December 3, 2018 |
| NCT00928018 | Completed | Phase 3 | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma | June 2009 | November 2014 |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT01000753 | Completed | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | May 30, 2005 | September 30, 2023 | |
| NCT01010295 | Completed | Phase 2 | A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae | September 2006 | May 2012 |
| NCT01018979 | Completed | Phase 2 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | February 2010 | October 2011 |
| NCT01030536 | Completed | Phase 1/Phase 2 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | February 15, 2010 | March 4, 2013 |
| NCT02529813 | Completed | Phase 1 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | December 16, 2015 | November 8, 2021 |
| NCT02543879 | Completed | Phase 1 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | September 2015 | March 2019 |
| NCT02566395 | Completed | Phase 3 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | December 2014 | February 14, 2022 |
| NCT02639559 | Completed | Phase 2 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | March 31, 2016 | April 7, 2023 |
| NCT02669017 | Completed | Phase 1 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | March 2016 | February 21, 2019 |
| NCT02710565 | Completed | N/A | Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma | February 2016 | July 2017 |
| NCT02767388 | Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery | September 1, 2016 | March 15, 2018 | |
| NCT02811679 | Completed | Phase 2 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma | August 2016 | December 2023 |
| NCT02955043 | Completed | N/A | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | December 22, 2016 | October 26, 2018 |
| NCT03019666 | Completed | Phase 1 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | October 18, 2017 | August 15, 2022 |
| NCT03056339 | Completed | Phase 1/Phase 2 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | June 21, 2017 | March 6, 2023 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03127020 | Completed | Phase 2 | Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients | June 2016 | |
| NCT03255018 | Completed | Phase 2 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | February 15, 2018 | June 29, 2023 |
| NCT03297424 | Completed | Phase 1 | A Study of PLX2853 in Advanced Malignancies. | September 12, 2017 | June 7, 2021 |
| NCT03323541 | Completed | Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure | November 3, 2016 | December 31, 2016 | |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT03454451 | Completed | Phase 1 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | April 25, 2018 | February 19, 2023 |
| NCT03469921 | Completed | Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 | January 1, 2000 | December 31, 2016 | |
| NCT03610724 | Completed | Phase 2 | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients | February 15, 2019 | April 26, 2023 |
| NCT03794167 | Completed | Phase 2 | BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma | June 1, 2012 | November 30, 2018 |
| NCT03802955 | Completed | Phase 1 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | December 20, 2018 | November 1, 2021 |
| NCT03885947 | Completed | Phase 1 | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | February 21, 2019 | March 10, 2021 |
| NCT03923504 | Completed | N/A | Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx | May 10, 2019 | April 18, 2022 |
| NCT03925935 | Completed | Phase 1 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | May 7, 2019 | November 8, 2021 |
| NCT04136756 | Completed | Phase 1 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | October 7, 2019 | April 24, 2023 |
| NCT04478123 | Completed | Phase 2 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | July 14, 2020 | June 8, 2023 |
| NCT04666025 | Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer | September 23, 2020 | May 5, 2023 | |
| NCT05332054 | Enrolling by invitation | Long-Term Follow-up Study | March 16, 2022 | December 2041 | |
| NCT06447376 | Not yet recruiting | Phase 1 | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | August 1, 2024 | September 1, 2028 |
| NCT06418204 | Not yet recruiting | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | August 2024 | August 2028 | |
| NCT06176690 | Not yet recruiting | Phase 1 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | June 1, 2024 | June 1, 2043 |
| NCT06343311 | Not yet recruiting | Phase 1/Phase 2 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | June 15, 2024 | December 31, 2027 |
| NCT06005649 | Not yet recruiting | Phase 1/Phase 2 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | August 31, 2024 | September 2026 |
| NCT05583071 | Not yet recruiting | Phase 2 | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | May 2024 | April 2027 |
| NCT05994157 | Not yet recruiting | Phase 1 | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | April 2024 | January 2028 |
| NCT05443165 | Not yet recruiting | N/A | The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients | January 31, 2024 | June 30, 2024 |
| NCT05921812 | Not yet recruiting | N/A | Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients | February 1, 2024 | October 1, 2024 |
| NCT05605119 | Recruiting | Phase 1 | First in Human, Dose Escalation, Dose Expansion Study of AUR105 | November 30, 2022 | May 30, 2026 |
| NCT03223610 | Recruiting | Phase 1/Phase 2 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | February 9, 2018 | December 1, 2026 |
| NCT06018129 | Recruiting | Phase 1/Phase 2 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | September 21, 2023 | December 31, 2032 |
| NCT06026319 | Recruiting | Phase 1 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | October 26, 2023 | January 1, 2028 |
| NCT06037018 | Recruiting | Phase 1 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | August 7, 2023 | March 2026 |
| NCT06059391 | Recruiting | Phase 2 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | August 30, 2024 | January 1, 2028 |
| NCT06203652 | Recruiting | The Pathogenesis and Prognostic Factors of Lymphoma | June 5, 2023 | December 31, 2028 | |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT03666000 | Recruiting | Phase 1/Phase 2 | Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL | March 11, 2019 | June 2024 |
| NCT01853631 | Recruiting | Phase 1 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | February 2014 | February 2036 |
| NCT06277011 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | February 10, 2023 | May 15, 2025 |
| NCT06299462 | Recruiting | Phase 1/Phase 2 | PTCy and ATG for MSD and MUD Transplants | June 20, 2024 | June 1, 2031 |
| NCT06323525 | Recruiting | Phase 1/Phase 2 | TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | April 17, 2024 | April 25, 2027 |
| NCT06357754 | Recruiting | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy | October 6, 2023 | October 6, 2038 | |
| NCT01351545 | Recruiting | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | October 2011 | October 2041 | |
| NCT04072393 | Recruiting | N/A | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | January 15, 2021 | March 31, 2025 |
| NCT04099966 | Recruiting | Phase 2 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | April 1, 2021 | December 31, 2026 |
| NCT06393335 | Recruiting | Early Phase 1 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | May 15, 2024 | March 15, 2026 |
| NCT04227015 | Recruiting | Early Phase 1 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | January 8, 2020 | May 31, 2027 |
| NCT04356846 | Recruiting | Phase 1 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | May 1, 2020 | December 1, 2023 |
| NCT04537871 | Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | November 18, 2020 | December 4, 2024 | |
| NCT04601831 | Recruiting | Phase 1/Phase 2 | 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL | December 23, 2020 | December 2024 |
| NCT04684563 | Recruiting | Phase 1 | huCART19-IL18 in NHL/CLL Patients | May 6, 2021 | May 2036 |
| NCT04689204 | Recruiting | Early Phase 1 | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies | December 29, 2020 | May 31, 2027 |
| NCT04718675 | Recruiting | Phase 1/Phase 2 | A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | February 8, 2021 | December 2025 |
| NCT04739813 | Recruiting | Phase 1 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | July 9, 2021 | July 15, 2029 |
| NCT04957901 | Recruiting | The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Mature B Cell Non-Hodgkins Lymphoma (NHL). | December 1, 2021 | June 1, 2026 | |
| NCT05005299 | Recruiting | Phase 1 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | June 8, 2022 | March 31, 2026 |
| NCT05006716 | Recruiting | Phase 1/Phase 2 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | September 13, 2021 | March 31, 2028 |
| NCT05019976 | Recruiting | N/A | Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma | September 30, 2021 | December 1, 2027 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05044039 | Recruiting | Phase 1 | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | February 28, 2022 | May 31, 2030 |
| NCT05053100 | Recruiting | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | August 17, 2021 | August 18, 2025 | |
| NCT05093335 | Recruiting | Early Phase 1 | In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET | October 1, 2021 | October 2025 |
| NCT05098613 | Recruiting | Phase 1 | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | December 21, 2021 | December 2025 |
| NCT05114330 | Recruiting | Secondary Central Nervous System Lymphoma Registry - Charité | June 8, 2011 | June 8, 2026 | |
| NCT05169515 | Recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | October 26, 2022 | July 15, 2028 |
| NCT05169658 | Recruiting | Phase 2 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | March 23, 2022 | December 1, 2025 |
| NCT05171647 | Recruiting | Phase 3 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | April 25, 2022 | November 30, 2027 |
| NCT05206357 | Recruiting | Phase 1 | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | October 4, 2022 | November 27, 2028 |
| NCT05207670 | Recruiting | Phase 2 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | February 1, 2022 | July 31, 2028 |
| NCT05253495 | Recruiting | Phase 2 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | February 1, 2022 | June 30, 2028 |
| NCT05283720 | Recruiting | Phase 2 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | June 14, 2022 | November 26, 2032 |
| NCT05294731 | Recruiting | Phase 1/Phase 2 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | March 24, 2022 | March 2027 |
| NCT05346809 | Recruiting | Phase 2 | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | March 31, 2023 | March 2025 |
| NCT05371054 | Recruiting | Phase 1/Phase 2 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | April 5, 2023 | March 10, 2025 |
| NCT05389423 | Recruiting | Phase 1 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | June 27, 2023 | June 1, 2032 |
| NCT05574114 | Recruiting | Phase 1 | A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma | October 5, 2022 | October 2025 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT05627856 | Recruiting | Phase 1/Phase 2 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | February 21, 2023 | February 2025 |
| NCT05643742 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | March 10, 2023 | February 2030 |
| NCT05664217 | Recruiting | Phase 2/Phase 3 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | December 23, 2022 | January 2029 |
| NCT05678998 | Recruiting | Phase 1 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | December 6, 2022 | December 2024 |
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT05794958 | Recruiting | Phase 1 | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | May 23, 2023 | April 1, 2038 |
| NCT02393157 | Recruiting | Phase 2 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | August 21, 2015 | December 2024 |
| NCT02287311 | Recruiting | Phase 1 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | February 2015 | March 2029 |
| NCT05896774 | Recruiting | Phase 1 | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | June 28, 2023 | May 27, 2025 |
| NCT05950165 | Recruiting | Phase 1/Phase 2 | A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | January 15, 2020 | February 2024 |
| NCT02917083 | Recruiting | Phase 1 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | May 8, 2017 | February 2040 |
| NCT05998642 | Recruiting | Phase 2 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | February 13, 2024 | December 31, 2028 |
| NCT06002828 | Recruiting | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | October 13, 2023 | February 1, 2030 | |
| NCT03125642 | Recruiting | Phase 2 | Auto Stem Cell Transplant for Lymphoma Patients | April 20, 2017 | April 30, 2026 |
| NCT06219356 | Recruiting | Phase 1 | A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas | January 11, 2024 | February 28, 2027 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT00471367 | Terminated | Phase 1 | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 | April 2007 | December 2008 |
| NCT01908387 | Terminated | Phase 1 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | July 2013 | July 2015 |
| NCT05127811 | Terminated | Phase 1 | A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma | October 21, 2021 | May 26, 2023 |
| NCT00019708 | Terminated | Phase 1 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | June 1999 | |
| NCT02519270 | Terminated | Phase 1 | Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects | May 1, 2016 | May 4, 2018 |
| NCT00383097 | Terminated | Phase 1 | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma | September 2006 | February 2010 |
| NCT03886649 | Terminated | Phase 1 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | November 4, 2019 | March 8, 2022 |
| NCT01998035 | Terminated | Phase 1/Phase 2 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | November 2013 | January 6, 2020 |
| NCT05205161 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | July 5, 2022 | August 17, 2023 |
| NCT00626444 | Terminated | Phase 2 | Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | February 2008 | December 2011 |
| NCT01343368 | Terminated | Phase 2 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | July 2011 | April 2015 |
| NCT04045028 | Terminated | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | July 22, 2019 | March 28, 2023 |
| NCT04083170 | Terminated | Phase 2 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | October 6, 2022 | November 30, 2022 |
| NCT00100737 | Terminated | Phase 2 | Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) | ||
| NCT05221385 | Terminated | Phase 1 | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma | April 12, 2021 | October 27, 2023 |
| NCT02568683 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | February 11, 2016 | June 22, 2017 |
| NCT03065790 | Terminated | Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide | February 6, 2017 | April 28, 2021 | |
| NCT01114256 | Terminated | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | March 2010 | January 2016 | |
| NCT04502706 | Terminated | Phase 1 | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | November 17, 2020 | March 31, 2022 |
| NCT04504708 | Terminated | Phase 1/Phase 2 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | February 17, 2021 | July 8, 2022 |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT05296525 | Terminated | Phase 1/Phase 2 | Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | July 5, 2022 | April 22, 2024 |
| NCT02080416 | Terminated | Early Phase 1 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | July 2014 | February 2016 |
| NCT03422679 | Terminated | Phase 1/Phase 2 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | December 5, 2017 | November 11, 2022 |
| NCT03379051 | Terminated | Phase 1/Phase 2 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | March 27, 2018 | June 16, 2022 |
| NCT03311126 | Terminated | Phase 2 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | October 19, 2017 | July 31, 2023 |
| NCT03272633 | Terminated | Early Phase 1 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | October 26, 2020 | September 22, 2022 |
| NCT02702141 | Terminated | Phase 1 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | February 2016 | July 10, 2018 |
| NCT03615105 | Terminated | Phase 2 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | July 25, 2018 | March 6, 2024 |
| NCT03645395 | Terminated | Phase 2 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) | April 8, 2019 | March 10, 2021 |
| NCT03602131 | Unknown status | Phase 2 | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | January 1, 2019 | March 30, 2021 |
| NCT04169932 | Unknown status | Early Phase 1 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | November 22, 2019 | November 22, 2022 |
| NCT05066958 | Unknown status | Phase 1/Phase 2 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | September 16, 2021 | December 1, 2022 |
| NCT03790891 | Unknown status | Early Phase 1 | Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | January 5, 2019 | January 1, 2022 |
| NCT03260231 | Unknown status | N/A | Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma | May 12, 2017 | December 31, 2021 |
| NCT00328237 | Unknown status | Phase 2 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | November 2005 | |
| NCT03088709 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | January 18, 2017 | January 31, 2022 |
| NCT01562509 | Unknown status | N/A | PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care | October 2012 | December 2014 |
| NCT01019863 | Unknown status | Phase 2 | Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma. | October 2008 | October 2011 |
| NCT01178658 | Unknown status | Phase 2 | Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma | July 2010 | |
| NCT02788084 | Unknown status | Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow | October 2016 | June 2021 | |
| NCT01178645 | Unknown status | Phase 2 | Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma | July 2010 | |
| NCT01914744 | Unknown status | Phase 2 | Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL | February 2013 | December 2016 |
| NCT00429065 | Unknown status | Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. | January 2007 | January 2007 | |
| NCT02736357 | Withdrawn | The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study | July 1, 2015 | April 17, 2023 | |
| NCT04684979 | Withdrawn | Phase 2 | Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies | March 28, 2022 | March 2027 |
| NCT03438344 | Withdrawn | Phase 2 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | December 2018 | December 2021 |
| NCT02657447 | Withdrawn | Phase 1 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | December 19, 2017 | September 2020 |
| NCT00837174 | Withdrawn | Phase 2 | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study | June 2010 | May 2012 |
| NCT05169151 | Withdrawn | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study | February 17, 2022 | April 18, 2023 | |
| NCT04293900 | Withdrawn | Diet, Physical Activity and Body Composition Changes During R-CHOP | January 2021 | December 2023 | |
| NCT03768310 | Withdrawn | Phase 1 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | June 2022 | August 2040 |
| NCT02640833 | Withdrawn | Phase 1 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | July 2016 | February 2021 |
| NCT01479582 | Withdrawn | Phase 2 | Providing Access to Cord Blood Units for Transplants | October 27, 2011 | November 26, 2012 |
| NCT02141100 | Withdrawn | Phase 1/Phase 2 | Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma | July 2014 | October 2016 |
| NCT02115126 | Withdrawn | Phase 2 | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant | December 2016 | January 2025 |
- Disase is a (Disease Ontology)
- DOID:0060058
- Cross Reference ID (Disease Ontology)
- ICD10CM:C85.9
- Cross Reference ID (Disease Ontology)
- ICDO:9591/3
- Cross Reference ID (Disease Ontology)
- MESH:D008228
- Cross Reference ID (Disease Ontology)
- MIM:605027
- Cross Reference ID (Disease Ontology)
- NCI:C3211
- Cross Reference ID (Disease Ontology)
- ORDO:547
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118601006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0024305
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012539
- OrphaNumber from OrphaNet (Orphanet)
- 547